Advertisement

Population-based estimates of the burden of pneumonia hospitalizations in Hong Kong, 2011–2015

  • Xue Li
  • Joseph E. Blais
  • Ian C. K. Wong
  • Anthony W. Y. Tam
  • Benjamin J. Cowling
  • Ivan F. N. Hung
  • Esther W. Y. ChanEmail author
Original Article

Abstract

Up-to-date data on the burden of disease are important to identify patients with unmet needs and to optimize healthcare resources. We aimed to characterize the burden of pneumonia hospitalizations in Hong Kong and inform targeted healthcare policies for pneumonia control in the era of global aging. This was a population-based study using a territory-wide administrative electronic health record system that covers all public hospitals of Hong Kong. Patients admitted to public hospitals, from 2011 to 2015, with a diagnosis of pneumonia at discharge were identified based on the International Classification of Diseases-Ninth Revision-Clinical Modification Codes (480–486 and 487.0). Incidence, inpatient case-fatality, all-cause fatality, 28-day readmission, hospital length of stay, and healthcare costs were assessed for seven age strata. We identified 323,992 patients (median age 80 years, 44.4% female) with hospitalized pneumonia (organism unspecified 84.2%; bacterial pneumonia 12.3%; viral pneumonia 2.5%; others 1.0%). Annual incidence was 955.1 per 100,000 population, with a 10.6% decrease from 2011 to 2015. Case-fatality, all-cause fatality, and 28-days readmission risks were 13.8, 21.6, and 19.5%, respectively. The average hospital length of stay was 14.1 days with corresponding direct costs of $9348 USD per episode in the monetary value of 2015. Individuals aged ≥ 65 years accounted for over 75% of pneumonia-related hospitalizations, 90% of deaths, and the majority of healthcare costs. Hospitalized pneumonia represents a considerable health and economic burden in Hong Kong, especially in older adults. The study provides a population-level baseline estimate for further cost-effective evaluation of targeted strategies for pneumonia control.

Keywords

Pneumonia admission Burden of disease Healthcare resource Elderly care Population aging 

Notes

Acknowledgments

We thank Dr. Hou Jing from the Department of Family Medicine and General Out-patient Clinic, Kowloon Central Cluster, Hospital Authority for her clinical advice on clinical and economic burden estimation. We acknowledge Dr. In Hye Suh from the Department of Pharmacology and Pharmacy, University of Hong Kong, for proof-reading of the manuscript.

Author contributions

Conception and design of the work: ICW, BJC, IFH, and EWC; data collection and analysis: XL and AWT; results interpretation: all authors; drafting the article: XL; critical revision of the article: XL, JB, BJC, IFH, and EWC; study supervision: EWC. Final approval of the version to be published: all authors.

Funding information

This work was partially supported by an Investigator-Initiated Research Grant from Pfizer Corporation Hong Kong Limited (grant number: WI214458). Pfizer had no role in the study design, data collection, statistical analysis, interpretation, or writing of the manuscript. The corresponding author was responsible for the content of the manuscript and the decision to submit for publication.

Compliance with ethical standards

Ethical approval and consent to participate

The study was approved by the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (reference number: UW16-327). Informed patient consent was waived as the data used in this study were de-identified.

Consent for publication

Not applicable.

Competing interests

EWC has received the Early Career Scheme and the General Research Fund from the Hong Kong Research Grants Council; Health and Medical Research Fund from the Food and Health Bureau of Hong Kong; internal funding from The University of Hong Kong; and research funding from Bristol-Myers Squibb, Pfizer, and Janssen, all unrelated to the current work. BJC has received research funding from Sanofi Pasteur and consulting fees from Roche, all unrelated to the current work. The other co-authors declare that they have no conflict of interest.

Supplementary material

10096_2018_3459_MOESM1_ESM.docx (16 kb)
ESM 1 ICD-9-CM diagnostic/procedure codes for identifying medical conditions. List of International Classification of Diseases-Ninth Revision-Clinical Modification (ICD-9-CM) codes used for identifying the medical conditions of target patients (DOCX 15 kb)
10096_2018_3459_MOESM2_ESM.docx (16 kb)
ESM 2 British National Formulary categories for relevant antimicrobials (5.1–5.3). List of British National Formulary categories for identifying the antimicrobial treatments of target patients (DOCX 16 kb)
10096_2018_3459_MOESM3_ESM.docx (16 kb)
ESM 3 Pneumonia-type distribution based on ICD9-CM Code. Detailed pneumonia-type distribution among the overall all-cause pneumonia (DOCX 15 kb)
10096_2018_3459_Fig4_ESM.png (147 kb)
ESM 4

Incidence of hospitalized pneumonia by age and sex. Middle line in the box: median value; upper and lower line of the box: interquartile ranges (PNG 146 kb)

10096_2018_3459_MOESM4_ESM.tiff (1.1 mb)
High-resolution image (TIFF 1078 kb)
10096_2018_3459_Fig5_ESM.png (53 kb)
ESM 5

Average length of stay of hospitalized pneumonia by age, 2011–2015 (PNG 52 kb)

10096_2018_3459_MOESM5_ESM.tiff (11.7 mb)
High-resolution image (TIFF 12003 kb)
10096_2018_3459_Fig6_ESM.png (49 kb)
ESM 6

Readmission of hospitalized pneumonia by age, 2011–2015 (PNG 49 kb)

10096_2018_3459_MOESM6_ESM.tiff (11.7 mb)
High-resolution image (TIFF 12003 kb)

References

  1. 1.
    The World Health Organization The United Nations Children’s Fund Global action plan for prevention and control of pneumonia (GAPP) http://www.who.int/maternal_child_adolescent/documents/fch_cah_nch_09_04/en/ Accessed Jan 16, 2018
  2. 2.
    PL Ho, TC Wu, David VK Chao, Ivan FN Hung, Leo Lui, David C Lung, Tommy HC Tang, Alan KL Wu (ed) Reducing bacterial resistance with IMPACT http://www.chp.gov.hk/files/pdf/reducing_bacterial_resistance_with_impact.pdf Accessed 14 November 2017
  3. 3.
    Center for Health Protection, Department of Health, The Government of Hong Kong Special Administrative Region Number of deaths by leading causes of death, 2001–2016 http://www.chp.gov.hk/en/data/4/10/27/380.html Accessed May 12, 2017
  4. 4.
    Chan KCC, Subramanian R, Chong P, Nelson EAS, Lam HS, Li AM, Ip M (2016) Pneumococcal carriage in young children after introduction of PCV13 in Hong Kong. Vaccine 34:3867–3874CrossRefGoogle Scholar
  5. 5.
    Ho PL, Yung RW, Tsang DN, Que TL, Ho M, Seto WH, Ng TK, Yam WC, Ng WW (2001) Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 48:659–665CrossRefGoogle Scholar
  6. 6.
    Centre for Health Protection, Department of Health, The Government of Hong Kong Special Administrative Region Vaccination schemes at a glance http://www.chp.gov.hk/en/view_content/18870.html Accessed 3 November 2017
  7. 7.
    Mui LW, Chan AY, Lee A, Lee J (2013) Cross-sectional study on attitudes among general practitioners towards pneumococcal vaccination for middle-aged and elderly population in Hong Kong. PLoS One 8:e78210CrossRefGoogle Scholar
  8. 8.
    Liao Q, Cowling BJ, Lam WWT, Fielding R (2011) Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: a longitudinal study. PLoS One 6:e17713CrossRefGoogle Scholar
  9. 9.
    van Deursen AMM, Schurink-Van't Klooster TM, Man WH, van de Kassteele J, van Gageldonk-Lafeber AB, Bruijning-Verhagen P, de Melker HE, Sanders EAM, Knol MJ (2017) Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands. Vaccine 35:7107–7113CrossRefGoogle Scholar
  10. 10.
    Sogaard M, Nielsen RB, Schonheyder HC, Norgaard M, Thomsen RW (2014) Nationwide trends in pneumonia hospitalization rates and mortality, Denmark 1997–2011. Respir Med 108:1214–1222CrossRefGoogle Scholar
  11. 11.
    Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG (2013) US pneumonia hospitalizations, a decade of pneumococcal conjugate vaccine use. N Engl J Med 369:155–163CrossRefGoogle Scholar
  12. 12.
    Azmi S, Aljunid SM, Maimaiti N, Ali AA, Muhammad Nur A, De Rosas-Valera M, Encluna J, Mohamed R, Wibowo B, Komaryani K, Roberts C (2016) Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. Int J Infect Dis 49:87–93CrossRefGoogle Scholar
  13. 13.
    Ho PL, Chiu SS, Chow FK, Mak GC, Lau YL (2007) Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong. Vaccine 25:6837–6841CrossRefGoogle Scholar
  14. 14.
    Chiu SS, Ho PL, Khong PL, Ooi C, So LY, Wong WH, Chan EL (2016) Population-based incidence of community-acquired pneumonia hospitalization in Hong Kong children younger than 5 years before universal conjugate pneumococcal immunization. J Microbiol Immunol Infect 49:225–229CrossRefGoogle Scholar
  15. 15.
    Wong IO, Cowling BJ, Leung GM, Schooling CM (2012) Trends in mortality from septicaemia and pneumonia with economic development: an age-period-cohort analysis. PLoS One 7:e38988CrossRefGoogle Scholar
  16. 16.
    Yu R, Tam W, Woo J (2017) Trend of centenarian deaths in Hong Kong between 2001 and 2010. Geriatr Gerontol Int 17:931–936CrossRefGoogle Scholar
  17. 17.
    Lau WY, Chan EW, Cheung C et al (2017) Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA 317:1151–1158CrossRefGoogle Scholar
  18. 18.
    Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72CrossRefGoogle Scholar
  19. 19.
    Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW (2015) Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction. Am J Cardiol 116:1088–1092CrossRefGoogle Scholar
  20. 20.
    Krishna SG, Rawal V, Durkin C, Modi RM, Hinton A, Cruz-Monserrate Z, Conwell DL, Hussan H (2018) Weight loss surgery reduces healthcare resource utilization and all-cause inpatient mortality in morbid obesity: a propensity-matched analysis. Obes Surg 28:3213–3220Google Scholar
  21. 21.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457CrossRefGoogle Scholar
  22. 22.
    Census and Statistical Department, The Government of Hong Kong Special Administrative Region Population estimates table 002: population by age group and sex https://www.censtatd.gov.hk/hkstat/sub/sp150.jsp?tableID=002&ID=0&productType=8 Accessed November 27, 2018
  23. 23.
    Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Aboyans V, Adetokunboh O, Afshin A, Agrawal A et al (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1151–1210CrossRefGoogle Scholar
  24. 24.
    Nair H, Watts AT, Williams LJ, Omer SB, Simpson CR, Willocks LJ, Cameron JC, Campbell H (2016) Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children. BMC Infect Dis 16:390CrossRefGoogle Scholar
  25. 25.
    Department of Health, The Government of Hong Kong Special Administrative Region Health facts of Hong Kong http://www.dh.gov.hk/english/statistics/statistics_hs/files/Health_Statistics_pamphlet_E.pdf Accessed 8 May 2017
  26. 26.
    Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ (2015) Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. Vaccine 33:3193–3199CrossRefGoogle Scholar
  27. 27.
    McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G (2012) The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 30:2060–2067CrossRefGoogle Scholar
  28. 28.
    Wong ELY, Cheung AWL, Leung MCM, Yam CHK, Chan FWK, Wong FYY, Yeoh EK (2011) Unplanned readmission rates, length of hospital stay, mortality, and medical costs of ten common medical conditions: a retrospective analysis of Hong Kong hospital data. BMC Health Serv Res 11:149CrossRefGoogle Scholar
  29. 29.
    Census and Statistical Department, The Government of Hong Kong Special Administrative Region Hong Kong population projections 2017–2066 https://www.censtatd.gov.hk/hkstat/sub/sp190.jsp?productCode=B1120015 Accessed Nov 3, 2017
  30. 30.
    Kwok CL, Lee CKM, Lo WTL, Yip PSF (2017) The contribution of ageing to hospitalisation days in Hong Kong: a decomposition analysis. Int J Health Policy Manag 6:155–164CrossRefGoogle Scholar
  31. 31.
    Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K (2015) The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One 10:e0122247CrossRefGoogle Scholar
  32. 32.
    Drijkoningen JJ, Rohde GG (2014) Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 20(Suppl 5):45–51CrossRefGoogle Scholar
  33. 33.
    Bartlett JG (2011) Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 52:S296–S304CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Xue Li
    • 1
  • Joseph E. Blais
    • 1
  • Ian C. K. Wong
    • 1
    • 2
  • Anthony W. Y. Tam
    • 1
  • Benjamin J. Cowling
    • 3
  • Ivan F. N. Hung
    • 4
    • 5
  • Esther W. Y. Chan
    • 1
    Email author
  1. 1.Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Laboratory BlockUniversity of Hong KongHong Kong Special Administrative RegionChina
  2. 2.Research Department of Practice and PolicyUCL School of PharmacyLondonUK
  3. 3.WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of MedicineUniversity of Hong KongHong Kong Special Administrative RegionChina
  4. 4.Carol Yu Centre for Infection and Division of Infectious Diseases, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Queen Mary HospitalUniversity of Hong KongHong Kong Special Administrative RegionChina
  5. 5.Department of Medicine, Queen Mary HospitalUniversity of Hong KongHong Kong Special Administrative RegionChina

Personalised recommendations